17-AAG hydrochloride - CAS 911710-03-7
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
17-AAG hydrochloride
Catalog Number:
911710-03-7
Synonyms:
[(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate hydrochloride;Tanespimycin Hydrochloride;NSC 330507 Hydrochloride;CP 127374 Hydrochloride;17-(Allylamino)-17-desmethylgeldanamycin hydrochloride
CAS Number:
911710-03-7
Description:
17-AAG hydrochloride is a potent HSP90 inhibitor with IC50 value of 5 nM, which is a 100-fold higher binding affinity for HSP90 derived from tumour cells than that from normal cells. It is less toxic by binding to Hsp90 and altering its function. It causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells. It has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively. It displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice compared with that from the normal tissues in vivo.
Molecular Weight:
622.15
Molecular Formula:
C31H44ClN3O8
Quantity:
Milligrams-Grams
Quality Standard:
In-house standard
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC.Cl
InChI:
InChI=1S/C31H43N3O8.ClH/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35;/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38);1H/b11-9-,18-10+,20-15+;/t17-,19+,24
InChIKey:
VFOPOIJGNBNWPN-AFXVCOSJSA-N
Targets:
Hsp90
Chemical Structure
CAS 911710-03-7 17-AAG hydrochloride

Related Hsp90 Products


CAS 12772-57-5 Radicicol

Radicicol
(CAS: 12772-57-5)

Radiocicol is an antifungal antibiotic. It inhibits heat Hsp90 activity by binding to the ATP-binding pocket, subsequently suppressing cell transformation induc...

CAS 908112-43-6 SNX-2112

SNX-2112
(CAS: 908112-43-6)

SNX-2112 is an Hsp90 inhibitor which is currently undergoing multiple phase 1 clinical trials. In all cell lines, SNX-2112 led to degradation of MET, HER-2, EGF...

CAS 1253584-84-7 NMS-E973

NMS-E973
(CAS: 1253584-84-7)

NMS-E973 shows a widespread antiproliferative activity with an average IC50 of 1.6 μM, and induces the degradation of client protein.

CAS 2752-65-0 Gambogic acid

Gambogic acid
(CAS: 2752-65-0)

Gambogic acid is a natural product inhibitor of Hsp90.

MPC-0767
(CAS: 1310540-32-9)

MPC-0767 is a novel L-alanine ester pro-drug of MPC-3100, designed to have improved aqueous solubility compared to MPC-3100.

KF-25706
(CAS: 184537-25-5)

KF25706 is derivative of radicicol, binds to the Hsp90 chaperone machinery, IC50 39nM.

CAS 958025-66-6 MPC-3100

MPC-3100
(CAS: 958025-66-6)

MPC-3100 targets the N-terminal ATP-binding site of Hsp90 and blocks the activity of ATPase. In the Her2-luciferase degradation assay, MPC-3100 reduces this cli...

Ratester
(CAS: 854485-83-9)

Radester is a hybrid composed of radicicol's resorcinol and geldanamycin’s benzoquinone part structures and exhibits good cellular activity against MCF7 breast ...

CAS 1118915-78-8 STA-1474

STA-1474
(CAS: 1118915-78-8)

STA-1474 is a H2O soluble prodrug of ganetespib (formerly STA-9090). STA-1474 will metabolize to Ganetespib, which is a potent Hsp90 inhibitor previously shown ...

TAS-116
(CAS: 1260533-36-5)

TAS-116 is a inhibitor of Hsp90. It induces significant cytotoxicity in MM cells even in the presence of BMSCs, associates with downregulation of phospho-Akt an...

NW457
(CAS: 1373761-12-6)

NW-457 is a potent Hsp90 inhibitor with no detectable hepatocytotoxicity in vitro. It synergizes with ionizing irradiation to induce chromatin condensation, nuc...

CAS 1149705-71-4 XL888

XL888
(CAS: 1149705-71-4)

XL888 is an ATP-competitive inhibitor of Hsp90. Through this action, specific client proteins are degraded, leading to cell cycle arrest or apoptosis. XL888 is ...

Pochonin D
(CAS: 544712-82-5)

Pochocin D is a patent Hsp90 inhibitor. IC50 80.0nM.

CAS 467214-21-7 Alvespimycin HCl

Alvespimycin HCl
(CAS: 467214-21-7)

Alvespimycin hydrochloride is the hydrochloride salt of alvespimycin, an analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds...

CPUY201112
(CAS: 1860793-58-3)

CPUY201112 is an N-terminal Hsp90 inhibitor, which leads to decreased expression of Hsp90 client proteins and may result in increased tumor cell apoptosis.

CAS 747412-49-3 Luminespib

Luminespib
(CAS: 747412-49-3)

Luminespib, also known as AUY-922 (or NVP-AUY922), is a derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with po...

CAS 73341-72-7 Macbecin I

Macbecin I
(CAS: 73341-72-7)

Macbecin I is an ansamycin antibiotic compound that inhibits Hsp90 by binding to the ATP-binding site.IC50 = 2μM. Exhibits antitumor and cytocidal activities (I...

CAS 64202-81-9 17-AG

17-AG
(CAS: 64202-81-9)

An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhi...

CAS 848695-25-0 BIIB021

BIIB021
(CAS: 848695-25-0)

BIIB021 is An orally active, purine-scaffold, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. BIIB021 that is ...

C086
(CAS: 1160107-44-7)

C086 inhibits Hsp90 and BCR-ABL, resulting in decreased proliferation of tumor cells, including imatinib-resistant cells.

Reference Reading


1.A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
Wagner AJ1, Chugh R, Rosen LS, Morgan JA, George S, Gordon M, Dunbar J, Normant E, Grayzel D, Demetri GD. Clin Cancer Res. 2013 Nov 1;19(21):6020-9. doi: 10.1158/1078-0432.CCR-13-0953. Epub 2013 Sep 17.
PURPOSE: Heat shock protein 90 (HSP90) is required for the proper folding, function, and stability of various client proteins, two of which (KIT and PDGFRα) are critical in the pathogenesis and progression of gastrointestinal stromal tumors (GIST). This phase I study investigated the safety and maximum tolerated dose (MTD) of retaspimycin hydrochloride (IPI-504), a novel potent and selective HSP90 inhibitor, in patients with metastatic and/or unresectable GIST or other soft-tissue sarcomas (STS).
2.Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
Madrigal-Matute J1, López-Franco O, Blanco-Colio LM, Muñoz-García B, Ramos-Mozo P, Ortega L, Egido J, Martín-Ventura JL. Cardiovasc Res. 2010 May 1;86(2):330-7. doi: 10.1093/cvr/cvq046. Epub 2010 Feb 12.
AIMS: Heat shock protein 90 (HSP90) is a ubiquitous chaperone involved in the folding, activation, and assembly of many proteins. HSP90 inhibitors [17-allylamino-17-demethoxygeldamycin (17-AAG)/17-dimethyl aminothylamino-17-demethoxygeldanamycin hydrochloride (17-DMAG)] bind to and inactivate HSP90, increasing the heat shock response and suppressing different signalling pathways. We aim to investigate the effect of HSP90 inhibitors in the modulation of inflammatory responses during atherogenesis.
3.Gateways to clinical trials.
Tomillero A, Moral MA. Methods Find Exp Clin Pharmacol. 2009 Sep;31(7):463-93.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: AAV1/SERCA2a, Abacavir sulfate/lamivudine, Adalimumab, Aliskiren fumarate, Ambrisentan, Aripiprazole, AT-7519, Atazanavir sulfate, Atomoxetine hydrochloride, Azacitidine, Azelnidipine; Besifloxacin hydrochloride, Bevacizumab, Bioabsorbable everolimus-eluting coronary stent, Bortezomib, Bosentan, Budesonide/formoterol fumarate; CAIV-T, Carisbamate, Casopitant mesylate, Certolizumab pegol, Cetuximab, Ciclesonide, Ciprofloxacin/dexamethasone, CTCE-9908; Dalcetrapib, Darunavir, Deferasirox, Desloratadine, Disitertide, Drotrecogin alfa (activated), DTA-H19, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Efalizumab, Emtricitabine, Eribulin mesilate, Escitalopram oxalate, Eszopiclone, EUR-1008, Everolimus-eluting coronary stent, Exenatide; Fampridine, Fluticasone furoate, Formoterol fumarate/fluticasone propionate, Fosamprenavir calcium, Fulvestrant; Gabapentin enacarbil, GS-7904L; HPV-6/11/16/18, Human Secretin, Hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, Imexon, Inalimarev/Falimarev, Indacaterol, Indacaterol maleate, Inhalable human insulin, Insulin detemir, Insulin glargine, Ixabepilone; L-Alanosine, Lapatinib ditosylate, Lenalidomide, Levocetirizine dihydrochloride, Liraglutide, Lisdexamfetamine mesilate, Lopinavir, Loratadine/montelukast sodium, Lutropin alfa; MeNZB, Mepolizumab, Micafungin sodium, Morphine hydrochloride; Nabiximols, Nikkomycin Z; Olmesartan medoxomil, Omalizumab; Paclitaxel-eluting stent, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Perifosine, PF-489791, Plitidepsin, Posaconazole, Pregabalin; QAX-576; Raltegravir potassium, Ramelteon, Rasagiline mesilate, Recombinant human relaxin H2, rhGAD65, Rivaroxaban, Rosuvastatin calcium, Rotigotine; Saxagliptin, SCH-530348, Sirolimus-eluting stent, SLIT-amikacin, Sorafenib, Sotrastaurin, SR-16234, Sulforaphane; Tadalafil, Tanespimycin, Tapentadol hydrochloride, Teriparatide, Tesofensine, Tiotropium bromide, Tipifarnib, Tirapazamine, TMC-207, Tocilizumab, Tolvaptan, Tosedostat, Treprostinil sodium; Ustekinumab; Varespladib methyl, Vicriviroc, Vildagliptin, Vildagliptin/metformin hydrochloride, Volociximab, Voriconazole; Ziconotide, Ziprasidone hydrochloride.